Close Menu

Takara Bio

Product Watch: Mar 31, 2011


WaferGen's SmartChip human microRNA panel V2; Asuragen's microRNA biofluids service.

WaferGen, Asuragen

NuGen and WaferGen Biosystems are collaborating to develop and market workflows that combine NuGen's sample prep and preamplification technology with WaferGen's SmartChip high-density and –throughput real-time PCR system.

The deal will enable researchers to more easily perform high-throughput, high-density real-time PCR with small, degraded, and hard-to-replace specimens, including formalin-fixed, paraffin-embedded tissue.

WaferGen's fourth-quarter revenues more than tripled and full-year revenues grew more than five-fold, primarily due to sales of its SmartChip products and services; but its net loss mounted as it pumped cash into the commercial launch and marketing of the SmartChip system.

The firm launched its SmartChip Real-Time PCR System in August 2010 and exceeded its revenue guidance for the year.

People in the News: Mar 2, 2011


Michael Bates named VP of oncology R&D at Cepheid; IntegenX appoints Dennis Harris as CSO; Timothy Triche joins WaferGen Biosystems' board of directors; Diffinity Genomics appoints John Foskett and Robert Evans to board.

Paired Ends: Mar 1, 2011


Dennis Harris, Jay Shendure, Mårten Winge, Maria Hjortsmark, Timothy Triche, Timothy Rink

According to the company's earnings statement, MDxHealth's product and service revenues nearly doubled – from €1 million in 2009 to €2 million in 2010 – due to several companion diagnostics deals and biomarker licensing agreements inked with major drug companies.

Reuben Dharmaraj, Erich Hunziker, Alan Hippe, Arul Chinnaiyan


Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.